In vitro evaluation of new surface coatings for extracorporeal circulation

Cardiopulmonary bypass (CPB) exposes blood to large, foreign surfaces. This exposure may activate the cellular and humoral inflammatory systems, resulting in inflammatory reactions and organ dysfunction. Coating the inner surfaces of the bypass circuit may help alleviate these side-effects. The objective of this study was to determine the influence of two new surface treatments on blood cell and complement activation. Oxygenator and tubing sets coated with synthetic polymers (n = 7) or heparin (n = 7) were compared to uncoated sets (n = 7) in an in vitro model of CPB. The circuits were run at 4 l/min and recirculated for 120 min. The inflammatory response was assessed at regular intervals by platelet counts, and activation of complement, leucocytes and platelets. We found that the median platelet counts decreased from 127 to 122 × 109/l (not significant, NS) in the synthetic polymer sets, from 96 to 88 × 109/l (NS) in the heparin-coated sets, and from 93 to 54 × 109/l (p < 0.01) in the uncoated sets after 2 h of recirculation. There were significant differences in platelet counts between the coated sets and the uncoated set at end of experiments (p < 0.05). Beta-thromboglobulin (BTG) concentrations increased in the synthetic polymer sets from 166 to 352 ng/ml (p < 0.01), in the heparin coated sets from 336 to 1168 ng/ml (p < 0.01), and in the uncoated sets from 301 to 3149 ng/ml (p < 0.01) after 2 h of recirculation. The differences in BTG at termination of the experiments were significant among all three sets (p < 0.05). Myeloperoxidase (MPO) concentrations in the synthetic polymer sets increased from 63 to 86 μg/l (p < 0.01), in the heparin-coated sets from 90 to 208 μg/l (p < 0.01), and in the uncoated sets from 122 to 513 μg/l (p < 0.01) after 2 h of recirculation. The differences in MPO at termination of the experiments were significant among all three groups (p < 0.01). There were no significant differences at termination of the experiments among the three sets regarding complement activation as measured by C3 activation products and the terminal complement complex. We conclude that in the current in vitro model of a CPB circuit, the synthetic polymer coating and the heparin coating caused significantly less platelet loss and granulocyte and platelet activation than the uncoated surface (p < 0.05). The synthetic polymer coating caused significantly less granulocyte and platelet activation than the heparin coating (p < 0.05). There was moderate complement activation within each group, but no significant differences among the three groups.

[1]  J. H. Lee,et al.  Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. , 1989, Journal of biomedical materials research.

[2]  김영하,et al.  Evaluation of blood compatibility of PEO grafted and heparin immobilized polyurethanes. , 1989 .

[3]  W. van Oeveren,et al.  Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass , 1991 .

[4]  S. Frøland,et al.  Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.

[5]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.

[6]  E. Fosse,et al.  Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. , 1989, The Journal of thoracic and cardiovascular surgery.

[7]  J. Pincemail,et al.  Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. , 1991, The Journal of thoracic and cardiovascular surgery.

[8]  O. Meyer,et al.  [Complement activation during extracorporeal circulation. A model for understanding lesional pulmonary edema]. , 1984, La Revue de medecine interne.

[9]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[10]  J. W. Pate,et al.  Electrical potential differences across the normal aorta and aortic grafts of dogs. , 1953, The American journal of physiology.

[11]  S. Cooper,et al.  Anticoagulant effects of sulphonated polyurethanes. , 1992, Biomaterials.

[12]  T. Okano,et al.  Surfaces and Blood Compatibility Current Hypotheses , 1987 .

[13]  E. Fosse,et al.  Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. , 1995, The Annals of thoracic surgery.

[14]  T. Lea,et al.  Quantification in Enzyme‐Linked Immunosorbent Assay of a C3 Neoepitope Expressed on Activated Human Complement Factor C3 , 1988, Scandinavian journal of immunology.

[15]  G. Tangen,et al.  Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. , 1995, Circulation.

[16]  E. Fosse,et al.  A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. , 1995, Artificial organs.

[17]  A. Bantjes,et al.  Anticoagulant activity of a synthetic heparinoid in relation to molecular weight and N-sulfate content. , 1981, Journal of biomedical materials research.

[18]  V. Videm Heparin in Clinical Doses ‘Primes’ Granulocytes to Subsequent Activation as Measured by Myeloperoxidase Release , 1996, Scandinavian journal of immunology.

[19]  R. Dutton,et al.  Heparin Bonding on Colloidal Graphite Surfaces , 1963, Science.

[20]  Y. Ito,et al.  Synthesis and nonthrombogenicity of polyetherurethaneurea film grafted with poly(sodium vinyl sulfonate). , 1991, Journal of biomedical materials research.

[21]  V. Videm,et al.  Effects on complement, granulocytes and platelets of a leukocyte-depletion filter during in vitro extracorporeal circulation. , 1997, Scandinavian cardiovascular journal : SCJ.

[22]  P. Venge,et al.  Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. , 2008, Artificial organs.

[23]  P. Venge,et al.  Activation of inflammatory systems during cardiopulmonary bypass. , 1988, Scandinavian journal of thoracic and cardiovascular surgery.

[24]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[25]  S. Khuri,et al.  The Effects of Complement Activation During Cardiopulmonary Bypass: Attenuation by Hypothermia, Heparin, and Hemodilution , 1988, Annals of surgery.